UNSPSC 51281641: Capreomycin iia

This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C19H32N12O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38TL5Q9SM7, chemically known as cyclo(3-amino-l-alanyl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-(2s)-2-((4r)-2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl)glycyl-(2s)-2-amino-.beta.-alanyl-l-seryl), but more generally known as capreomycin iia, which bears US NIH Compound Identifier 3034236.

European Medicines Agency schedules capreomycin iia or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01028MIG. Most nations, for tariff purposes, schedule capreomycin iia under HS 29419000. SMILES: C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CN)CO)N)N.

UNSPSC 51281641 Capreomycin iia is a Commodity code that captures specialized pharmaceutical products procured by state and local health departments and county health systems. The recent opportunities tagged under this code show little direct alignment with capreomycin itself — a second-line tuberculosis treatment — and instead reflect state and local procurement of other essential pharmaceuticals through cooperative purchasing agreements and direct buys. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 covering Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets with a 12-month initial term and renewal options through year three. Issuing bodies include state health departments and county health systems managing inventory for community health initiatives and emergency preparedness, typically using cooperative purchasing vehicles or invitation-for-bid processes to source pharmaceuticals at scale.

Geographic activity centers on Illinois and Florida, with the Illinois Department of Public Health and Seminole County, Florida both actively procuring pharmaceutical supplies in the second and third quarters of 2026. Seminole County issued an IFB in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly delivery, a two-year initial term and one-year renewal option, and a response deadline of July 26, 2026. The code shows meaningful but limited recent state and local activity; vendors pursuing opportunities under this category should monitor cooperative purchasing consortiums like MMCAP Infuse and county health department RFBs for both routine pharmaceutical supplies and emergency response products.